B Gross, B Staels - Best Practice & Research Clinical Endocrinology & …, 2007 - Elsevier Patients with type-2 diabetes mellitus (T2DM) are considered to be at
particularly high risk for cardiovascular disease. Over the last decade, the
members of the peroxisome proliferator-activated receptor (PPAR) subfamily ... Cited by 19 - Related articles - All 15 versions
RA Middelburg, D van Stein, E Briet, JG van … - Transfusion, 2008 - critcaremed.com Middelburg, Rutger A.; van Stein, Daniëlle; Briët, Ernest; van der Bom,
Johanna G. ... From the Department of Clinical Epidemiology, Leiden University
Medical Center, and the Department of Research and Training, Sanquin Blood ... Cited by 13 - Related articles - Cached - All 7 versions
- ►prsjournal.net RD Sanders, J Weimann, M Maze - Anesthesiology, 2008 - journals.lww.com Nitrous oxide is the longest serving member of the anesthe- siologist's
pharmacologic armamentarium but remains a source of controversy because of fears
over its adverse effects. Re- cently, the Evaluation of Nitrous oxide In a ... Cited by 9 - Related articles - All 15 versions
GH Hao, XL Niu, DF Gao, J Wei, NP Wang - British Journal of Pharmacology, 2008 - pubmedcentral.nih.gov In growth-arrested cardiac fibroblasts, PPAR-γ ligands rosiglitazone and
15-deoxy-Δ 12,14 -prostaglandin J 2 (15d-PGJ 2 ) dose-dependently attenuated
Ang II-induced cell proliferation and expression of PAI-1, collagen type-I, ... Cited by 4 - Related articles - BL Direct - All 5 versions
- ►critcaremed.com A BORGHI-SILVA, CC Oliveira, C Carrascosa, J … - British Medical Journal, 2008 - thorax.bmj.com Online First articles must include the digital object identifier (DOIs) and date
of initial publication. establish publication priority; they are indexed by
PubMed from initial publication. Citations to may be posted when available ... Cited by 3 - Related articles - All 5 versions
- ►critcaremed.org RS Chima, PW Hake, G Piraino, P Mangeshkar … - Critical Care Medicine, 2008 - journals.lww.com Objective: Peroxisome proliferator-activated receptor- is a ligand-activated
transcription factor. Ciglitazone, a peroxisome pro- liferator-activated
receptor- ligand, has been shown to provide beneficial effects in ... Cited by 2 - Related articles - All 9 versions
M Mietus-Snyder, RM Krauss - Journal of Clinical Lipidology, 2008 - Elsevier Age remains one of the strongest risk factors for atherosclerotic disease, but
the protection conferred by youth can be eroded by cardiovascular risk factors
such as dyslipidemia. Elevated atherogenic lipoproteins and inadequate ... Cited by 1 - Related articles - All 25 versions
